H.C. Wainwright Sticks to Their Buy Rating for ADMA Biologics (ADMA)


H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ADMA Biologics (ADMA) today and set a price target of $10. The company’s shares closed yesterday at $4.

Selvaraju noted:

“We note that Perceptive Credit Holdings is an investment entity of Perceptive Life Advisors, which is one of ADMA’s largest institutional shareholders. In our view, Perceptive’s extension of credit to ADMA underscores the investor’s confidence in the company.”

According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.3% and a 31.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ADMA Biologics with a $11.25 average price target, implying a 181.3% upside from current levels. In a report issued on February 13, Oppenheimer also assigned a Buy rating to the stock with a $14 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.96 and a one-year low of $2.08. Currently, ADMA Biologics has an average volume of 442.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts